Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PTO Creates Task Force To Respond To Upcoming Bilski Decision

This article was originally published in The Pink Sheet Daily

Executive Summary

PTO wants government to back Myriad in its appeal of gene patent ruling, agency's Arti Rai says at BIO IP conference. PTO seeks to reduce patent pendency through patent reform and a fast-track review option.

You may also be interested in...



Patent Office Would Get Ability To Set Fees Under House Bill; PTO To Allow Applicants To Fast Track One Application By Dropping Another

Since Congress is still tussling over a comprehensive patent reform bill, House Judiciary Committee Chairman John Conyers and Ranking Member Lamar Smith, R-Texas, introduced a stand-alone measure that would give the U.S. Patent and Trademark Office the authority to set its own fees for a 10-year period

Patent Office Would Get Ability To Set Fees Under House Bill; PTO To Allow Applicants To Fast Track One Application By Dropping Another

Since Congress is still tussling over a comprehensive patent reform bill, House Judiciary Committee Chairman John Conyers and Ranking Member Lamar Smith, R-Texas, introduced a stand-alone measure that would give the U.S. Patent and Trademark Office the authority to set its own fees for a 10-year period

Patent Reform Bill Is Bogged Down, Rep. Conyers Reports At Hearing

Patent reform legislation appears to be held up over differences between the House and Senate versions of the bill

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS070539

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel